Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2266-2274

  Lee, Phillip D K ^a,b   Durham, Susan K ^a   Martinez, Victor ^c   Vasconez, Oswaldo ^c   Powell, David R ^a   Guevara Aguirre, Jaime ^c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Diagnostic Systems Laboratories Inc   (United States)

^c INSTITUTE OF ENDOCRINOLOGY   (Ecuador)

^d 6337 CCI Quito   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE RESPONSE; HUMAN; KINETICS; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; RECEPTORS, SOMATOTROPIN; RECOMBINANT PROTEINS; SOMATOMEDINS; TIME FACTORS;

EID: 0030835727     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2266     Document Type: Article

References (55)

1. Daughaday WH, Rotwein P. 1989 Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev. 10:68-91.
2. Cohen P, Rosenfeld RG. 1994 Physiological and clinical relevance of the IGFBPs. Curr Opin Pediatr. 6:462-467.
3. Rechler MM. 1993 Insulin-like growth factor binding proteins. Vit Horm. 47:1-114.
4. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. 1986 Insulin-like growth factors I and II in the evaluation of growth retardation. J Pediatr. 209:428-433.
5. Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG. 1991 Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. Pediatr Res. 27:45-51.
6. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. 1990 A specific radioimmunoassay for the growth hormone-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 70:1292.
7. Hasegawa Y, Hawegawa T, Tsuchiya Y. 1995 Clinical utility of total insulin-like growth factor-I and insulin-like growth factor binding protein-3 measurements in the evaluation of short children. Clin Pediatr Endocrinol. 4:103-113.
8. Lee PDK, Conover CA, Powell DR. 1993 Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med. 204:4-29.
9. Blum WF, Horn N, Kratzsch J, et al. 1993 Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul. 3:100-104.
10. Schwander J, Mary JL. 1993 The RIA for IGFBP-2 in man - a meagre catch? Growth Regul. 3:104-108.
11. Thissen JP, Ketelslegers JM, Underwood LE. 1994 Nutritional regulation of the insulin-like growth factors. Endocr Rev. 15:80-101.
12. Rosenfeld RG, Gargosky SE. 1996 Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls. J Pediatr. 128:552-557.
13. Guevara-Aguirre J, Rosenbloom A, Fielder P, Diamond Jr F, Rosenfeld R. 1993 Growth hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab. 76:417-423.
14. Guevara-Aguirre J, Vasconez O, Martinez V, et al. 1995 A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab. 80:1393-1398.
15. Lee PDK, Mistry J, Hintz RL. 1996 Active insulin-like growth factor-I (IGF-I) assays. Webster: DSL.
16. van Dessel HJHMT, Chandrasekher Y, Yap OWS, et al. 1996 Serum levels and follicular fluid levels of insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab. 81:1224-1231.
17. Schneiderman R, Rosenberg N, Hiss J, Lee P, Maroudas A. 1995 Concentration and size distribution of IGF-1 in human normal and osteoarthritic synovia! fluid and cartilage. Arch Biochem Biophys. 324:173-188.
18. Bereket A, Lang CH, Blethen SL, Co Ng L, Wilson TA. 1996 Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children. Clin Endocrinol (Oxf). 45:321-326.
19. Kale AS, Liu F, Hintz RL, et al. 1996 Characterization of insulin-like growth factors and their binding proteins in peritoneal dialysate. Pediatr Nephrol. 10:467-473.
20. Tanner JM, Davies PSW. 1985 Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 107:317-329.
21. Hintz RL, Rosenfeld RG, Wilson DM, et al. 1982 Biosynthetic methionyl human growth hormone is biologically active in adult man. Lancet. 1:1276-1279.
22. Kearns GL, Kemp SF, Frindik JP. 1991 Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab. 72:1148-1156.
23. Grant MB, Schmetz I, Russell B, Harwood HJ, Silverstein J, Merimee T. 1986 Changes in insulin-like growth factors I and II and their binding protein after a single intramuscular injection of growth hormone. J Clin Endocrinol Metab. 63:981-984.
24. Jørgensen JOL, Flyvbjerg A, Dinesen J, et al. 1987 Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in a double-blind crossover study. Acta Endocrinol (Copenh). 116:381-386.
25. Jørgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. 1988 Dose-response studies with biosynthetic human growth hormone in growth hormone deficient patients. J Clin Endocrinol Metab. 67:36-40.
26. Jørgensen JOL. 1991 Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev. 12:189-207.
27. Zeisel HJ, von Petrykowski W, Wais U. 1992 Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Horm Res. 37(Suppl 2):5-13.
28. Marcus R, Butterfield F, Holloway L, et al. 1990 Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 70:519-527.
29. Jørgensen JOL, Flyvbjerg A, Dinesen J, et al. 1987 Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man. Acta Endocrinol (Copenh). 116:381-386.
30. Laursen T, Jørgensen JOL, Jakobsen G, Hansen BL, Christiansen JS. 1995 Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab. 80:2410-2418.
31. Jørgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Ørskov H, Christiansen JS. 1988 Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab. 67:36-40.
32. Jørgensen JOL, Møller N, Lauritzen T, Alberti KGMM, Ørskov H, Christiansen JS. 1990 Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. 70:207-214.
33. Tapanainen J, Rönnberg L, Martikainen H, Reinilä M, Koistinen R, Seppälä M. 1991 Short and long-term effects of growth hormone on circulating levels of insulin-like growth factor-I (IGF-I), IGF-binding protein-1, and insulin: a placebo-controlled study. J Clin Endocrinol Metab. 73:71-74.
34. Møller J, Frandsen E, Fisker S, Jørgensen JOL, Christiansen JS. 1996 Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study. Clin Endocrinol (Oxf). 44:533-539.
35. Thompson JL, Butterfield GE, Marcus R, et al. 1995 The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab. 80:1845-1852.
36. Mandel S, Moreland E, Nichols V, Hanna C, LaFranchi S. 1995 Changes in insulin-like growth factor I (IGF-I), IGF-binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment. J Clin Endocrinol Metab. 80:190-194.
37. Copeland KC, Underwood LE, Van Wyk JJ. 1980 Induction of immunoreactive somatomedin C in human serum by growth hormone: dose response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab. 50:690-697.
38. D'Ercole AJ, Stiles AD, Underwood LE. 1984 Tissue concentrations of somatomedin-C: further evidence for multiple sites of synthesis and paracrine/ autocrine mechanisms of action. Proc Natl Acad Sci USA. 81:935-939.
39. Snyder DK, Clemmons DR, Underwood LE. 1988 Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J Clin Endocrinol Metab. 67:54-61.
40. Valk NK, van der Lely AJ, de Herder WW, Lindemans J, Lamberts SWJ. 1994 The effects of human growth hormone (GH) administration in GH-deficient adults: a 20-day metabolic ward study. J Clin Endocrinol Metab 79:1070-1076.
41. Zapf J, Hauri C, Waldvogel M, Froesch ER. 1986 Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest. 77:1768-1775.
42. Hintz RL, Liu F. 1980 Somatomedin plasma binding proteins. In: Pecile A, Müller EE, eds. Growth hormone and other biologically active peptides. Int Congr Ser 495. Amsterdam: Excerpta Medica; 133-143.
43. Hintz RL, Liu F, Rosenfeld RG, Kemp SF. 1981 Plasma somatomedin-binding proteins in hypopituitarism: Changes during growth hormone therapy. J Clin Endocrinol Metab. 53:100-104.
44. Clemmons DR, Snyder DK, Busby WH Jr. 1991 Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab. 73:727-733.
45. Bereket A, Wilson TA, Blethen SL, et al. 1996 Effect of short-term fasting on free/dissociable insulin-like growth factor 1 concentrations in normal human serum. J Clin Endocrinol Metab. 81:4379-4384.
46. Frystyk J, Skjærbæk C, Dinesen B, Ørskov H. 1994 Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348:185-191.
47. Conover CA, Butler PC, Wang M, Rizza RA, Lee PDK. 1990 Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans. Diabetes. 39:1251-1256.
48. Butler P, Kryshak E, Rizza R. 1991 Mechanism of growth hormone-induced postprandial carbohydrate intolerance in humans. Am J Physiol. 260:E513-520.
49. O'Neal DN, Kalfas A, Dunning PL, et al. 1994 The effect of 3 months of recombinant human growth hormone (GH) on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab. 79:975-983.
50. Weaver JU, Monson JP, Noonan K, et al. 1995 The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab. 80:153-159.
51. Hew FL, Koschmann M, Christopher M, et al. 1996 Insulin resistance in growth hormone deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab. 81:555-564.
52. Cotterill AM, Holly JMP, Taylor AM, et al. 1992 The insulin-like growth factor (IGF)-hinding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab. 74:56-63.
53. Fielder PJ, Guevara-Aguirre J, Rosenbloom AL, Carlsson L, Hintz RL, Rosenfeld RG. 1992 Expression of serum insulin-like growth factors, insulin-like growth factor-binding proteins, and the growth hormone-binding protein in heterozygote relatives of Ecuadorian growth hormone receptor deficient patients. J Clin Endocrinol Metab. 74:743-750.
54. Walker JL, Baxter RC, Young S, Pucilowska J, Clemmons DR, Underwood LE. 1993 Effects of recombinant insulin-like growth factor I on IGF binding proteins and the acid-labile subunit in growth hormone insensitivity syndrome. Growth Regul. 3:109-112.
55. Kastrup KW. 1983 Can somatomedin stimulation by hGH be used as a test? Pediatr Adolesc Endocrinol. 12:147-151.